Acute Placental Infection Due to Klebsiella pneumoniae: Report of a Unique Case

A 40-year-old woman, gravida 9, with seven healthy children and a history of one abortion (p 7 + 1) , presented at 18 weeks of gestation with fever and malodorous vaginal discharge. Ultrasound revealed a macerated fetus. The placenta showed acute chorioamnionitis and acute villitis with microabscess formation. Blood and vaginal cultures both grew Klebsiella pneumoniae. This is the first reported case in English literature of Klebsiella pneumoniae causing suppurative placentitis leading to fetal demise

c-Abl binding and phosphorylation of geminin Y150 in G₂/M/early G₁ cells promotes overexpressed geminin oncogenicity in HME cells.

<p>(A) Immunoprecipitation of cycling, G₀/G₁, S, G₂/M or M/G₁ HME cells with anti-Cdt1, -c-Abl, -Sp1 (negative control) and -geminin antibodies. (B) c-Abl immunoprecipitated from S or G₂/M HME cells (upper panels) was used to <i>in vitro</i> phosphorylate GST-WT-, -Y98A-, -Y111A-, -Y150A-geminin or GST-survivin (negative control, lower panels). (C) c-Abl immunoprecipitated from G₂/M was used to <i>in vitro</i> phosphorylate GST-WT-geminin in the presence of the increasing concentrations of CKII inhibitor, TBB (left panels) or c-Abl inhibitor, imatinib (right panels). (D) The percentage of p-(S10)-H3⁺-cells in HME, uninduced or induced Gem9 following transfection of si-control or si-c-Abl (for 72 hr) or treatment with vehicle or 5 µM of imatinib (during the last 24 h). Data are represented as mean ± SD of triplicates done three separate times, where *  =  <i>p</i>≤<i>0.05</i> and **  =  <i>p</i>≤<i>0.001</i>. (E) Metaphase spread analysis of chromosome condensation in uninduced or induced Gem9 cells before or after transfection of sic-Abl or treatment with 5 µM of imatinib. (F) FACS analysis of uninduced or induced Gem9 cells transfection of sic-Abl or treatment with 5 µM of imatinib. Aneuploid cells are shown in the red circles and their percentage is in insets. R1 = G₀/G₁, R3/R4/R5 = early/mid/late S, R2 = G₂/M and R6 = >4N cells. Experiments were done three separate times in triplicates.</p

Geminin Overexpression Promotes Imatinib Sensitive Breast Cancer: A Novel Treatment Approach for Aggressive Breast Cancers, Including a Subset of Triple Negative

<div><p>Breast cancer is the second leading cause of cancer-related deaths in women. Triple negative breast cancer (TNBC) is an aggressive subtype that affects 10–25% mostly African American women. TNBC has the poorest prognosis of all subtypes with rapid progression leading to mortality in younger patients. So far, there is no targeted treatment for TNBC. To that end, here we show that c-Abl is one of several tyrosine kinases that phosphorylate and activate geminin’s ability to promote TNBC. Analysis of >800 breast tumor samples showed that geminin is overexpressed in ∼50% of all tumors. Although c-Abl is overexpressed in ∼90% of all tumors, it is only nuclear in geminin overexpressing tumors. In geminin-negative tumors, c-Abl is only cytoplasmic. Inhibiting c-Abl expression or activity (using imatinib or nilotinib) prevented geminin Y150 phosphorylation, inactivated the protein, and most importantly converted overexpressed geminin from an oncogene to an apoptosis inducer. In pre-clinical orthotopic breast tumor models, geminin-overexpressing cells developed aneuploid and invasive tumors, which were suppressed when c-Abl expression was blocked. Moreover, established geminin overexpressing orthotopic tumors regressed when treated with imatinib or nilotinib. Our studies support imatinib/nilotonib as a novel treatment option for patients with aggressive breast cancer (including a subset of TNBCs)-overexpressing geminin and nuclear c-Abl.</p></div

Stabilization of geminin protein by c-Abl phosphorylation and the expression of geminin and c-Abl in breast cancer cell lines.

<p>(A) The expression level of geminin in naïve HME, uninduced and induced Gem9 cells following c-Abl silencing or inactivation using imatinib or transfection of the dominant negative c-Abl (K290R). (B) The expression of c-Abl, geminin, p-CrkII in induced Gem9, MCF7 or MDA-MB-231 cells silenced from c-Abl or treated with imatinib. (C) The expression level of c-Abl, p-CrkII and geminin in induced Gem9 or MDA-MB-231 cells silenced of c-Abl or treated with nilotinib. (D) RT/PCR analysis of geminin mRNA in uninduced, induced Gem9 or MDA-MB-231 cells in the presence of vehicle or imatinib. (E) The expression of geminin in naïve HME or induced Gem9 cells in the presence of vehicle, imatinib or imatinib + MG132. (F) The expression of c-Abl and geminin mRNAs and proteins (inset) in several breast cancer cell lines. Note that Hs578T cells express high level of geminin mRNA, but no protein. (G) The re-expression of geminin in Hs578T cells reconstituted with WT and not kinase dead (KD) c-Abl (left). The re-expression of geminin in Hs578T cells reconstituted with WT or constitutively active (CA) c-Abl was blocked by imatinib (right). (H) The expression of endogenous (left) or overexpressed (right) geminin in MDA-MB-231 cells following treatment with the translational inhibitor cycloheximide (CHX) for 0-10 h with cells collected at 2 h intervals. (I) The expression of exogenous Myc tagged WT- (left), Y150A- (middle) or Y150E- (right)-geminin following no treatment (1^st lanes), 10 h of CHX (2^nd lanes), 10 h CHX followed by 24 h of complete serum (3^rd lanes) or 10 h CHX followed by 24 h of complete serum + 10 µM of imatinib (4^th lanes).</p

c-Abl silencing or inactivation promotes cell death, specifically, in geminin overexpressing cells and prevents transformation.

<p>(A) Phase contrast images showing naïve HME, uninduced and induced Gem9 cultures following transfection of sic-Abl or treatment with 10 µM of imatinib. Scale bar  =  50 µm. (B) Representative images showing TUNEL⁺-cells in naïve HME, uninduced and induced Gem9 cultures following transfection of sic-Abl or treatment with 10 µM of imatinib. Inset is DAPI stained cells in the corresponding images. Scale bar  =  100 µm. (C) Number of TUNEL⁺-cells in naïve HME, uninduced and induced Gem9 cultures after c-Abl silencing or inactivation with imatinib. Data are represented as mean ± SD of triplicates done 3 separate times, where **  =  <i>p</i>≤<i>0.01</i> and ***  =  <i>p</i>≤<i>0.0001</i>.</p

The expression of geminin and c-Abl in breast tumor samples.

<p>(A) The normalized expression of geminin and c-Abl mRNA in normal (n = 5), luminal A (n = 7), luminal B (n = 9), Her2⁺ (n = 11) and TN/BL (n = 7) tumor samples. (B) Box plot of gene expression for combined gene set of geminin and c-Abl across cell lines grouped into clinical subtypes; triple negative breast cancer (TNBC, red), HER2-positive (HER2, yellow), and ER-positive (ER⁺, blue) based on annotation data from (38). (C) Number of total, geminin-positive and c-Abl-positive tumors detected using immunohistochemistry on normal/cancer adjacent (n = 66), DCIS (n = 180), invasive (n = 100) and metastatic (n = 165) breast tumors. (D) Representative immunohistochemical staining images of geminin (1 and 3) or -c-Abl (2 and 4) on invasive breast tumor samples. Scale bar  =  50 µm. (E) Number of geminin-positive or -negative in Her2⁺ (n = 32) or TN/BL (n = 72) showing cytoplasmic (Cyt), nuclear (Nuc), or both (Cyt + Nuc) c-Abl expression. (F) The level of geminin and c-Abl in the nuclear or cytoplasmic fractions of the indicated cell lines.</p

The effect of c-Abl silencing or inactivation on geminin-driven mammary tumors.

<p>(A, left) The volumes of geminin-driven orthotopic tumors following expression of sh-control (black line, n  = 10), shc-Abl (green line, n = 10) or sh-geminin (red line, n = 10) in Gem9 cells. All mice were kept on doxycycline containing drinking water throughout the experiment. A set of 10 mice were injected with Gem9 cells and kept on no doxycycline water (purple line). (A, right) Representative luciferase images taken at day 45 of tumors shown in (A, left). (B, left) The volumes of MDAMB231 orthotopic tumors following treatment with vehicle (black line, n  = 10), imatinib (red line, n = 10) or nilotinib (green line, n = 10). (B, right) Representative luciferase images taken at day 12 of tumors shown in (B, left).</p

c-Abl binding and phosphorylation of geminin Y150 in G₂/M/early G₁ cells promotes overexpressed geminin oncogenicity in HME cells.

<p>(A) Immunoprecipitation of cycling, G₀/G₁, S, G₂/M or M/G₁ HME cells with anti-Cdt1, -c-Abl, -Sp1 (negative control) and -geminin antibodies. (B) c-Abl immunoprecipitated from S or G₂/M HME cells (upper panels) was used to <i>in vitro</i> phosphorylate GST-WT-, -Y98A-, -Y111A-, -Y150A-geminin or GST-survivin (negative control, lower panels). (C) c-Abl immunoprecipitated from G₂/M was used to <i>in vitro</i> phosphorylate GST-WT-geminin in the presence of the increasing concentrations of CKII inhibitor, TBB (left panels) or c-Abl inhibitor, imatinib (right panels). (D) The percentage of p-(S10)-H3⁺-cells in HME, uninduced or induced Gem9 following transfection of si-control or si-c-Abl (for 72 hr) or treatment with vehicle or 5 µM of imatinib (during the last 24 h). Data are represented as mean ± SD of triplicates done three separate times, where *  =  <i>p</i>≤<i>0.05</i> and **  =  <i>p</i>≤<i>0.001</i>. (E) Metaphase spread analysis of chromosome condensation in uninduced or induced Gem9 cells before or after transfection of sic-Abl or treatment with 5 µM of imatinib. (F) FACS analysis of uninduced or induced Gem9 cells transfection of sic-Abl or treatment with 5 µM of imatinib. Aneuploid cells are shown in the red circles and their percentage is in insets. R1 = G₀/G₁, R3/R4/R5 = early/mid/late S, R2 = G₂/M and R6 = >4N cells. Experiments were done three separate times in triplicates.</p